A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The Phase III trial ...

Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...

Neutrophils cause time-of-day–dependent collateral tissue damage after sterile injury through an intrinsic circadian program.

A joint research team from NIMS, The University of Tokyo, Kyoto Institute of Technology and Tohoku University has ...

Silverback Webinar has released an expanded version of its webinar software, introducing updated capabilities intended to support the growing demand for structured, reliable, and interactive virtual ...

Behind the hits and hero worship, these 15 bands were war zones of ego, excess, betrayal and dysfunction For every glorious ...

A monitor node validates state proofs and anchors snapshots on chain, which provides auditability for attribution and ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...